{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,12]],"date-time":"2026-02-12T09:22:01Z","timestamp":1770888121762,"version":"3.50.1"},"reference-count":34,"publisher":"Springer Science and Business Media LLC","issue":"1","content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Cancer"],"published-print":{"date-parts":[[2017,12]]},"DOI":"10.1186\/s12885-017-3715-5","type":"journal-article","created":{"date-parts":[[2017,11,6]],"date-time":"2017-11-06T11:50:06Z","timestamp":1509969006000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":18,"title":["Constitutional mutation in CDKN2A is associated with long term survivorship in multiple myeloma: a case report"],"prefix":"10.1186","volume":"17","author":[{"given":"Vallari","family":"Shah","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kevin D.","family":"Boyd","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Richard S.","family":"Houlston","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Martin F.","family":"Kaiser","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2017,11,6]]},"reference":[{"issue":"1","key":"3715_CR1","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1185\/03007995.2015.1105202","volume":"32","author":"X Song","year":"2016","unstructured":"Song X, Cong Z, Wilson K. Real-world treatment patterns, comorbidities, and disease-related complications in patients with multiple myeloma in the United States. Curr Med Res Opin. 2016;32(1):95\u2013103.","journal-title":"Curr Med Res Opin"},{"issue":"9","key":"3715_CR2","doi-asserted-by":"crossref","first-page":"1680","DOI":"10.1001\/jama.1969.03160090040009","volume":"208","author":"R Alexanian","year":"1969","unstructured":"Alexanian R, et al. Treatment for multiple myeloma. Combination chemotherapy with different melphalan dose regimens. JAMA. 1969;208(9):1680\u20135.","journal-title":"JAMA"},{"issue":"1","key":"3715_CR3","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1016\/j.mayocp.2015.11.007","volume":"91","author":"SV Rajkumar","year":"2016","unstructured":"Rajkumar SV, Kumar S. Multiple myeloma: diagnosis and treatment. Mayo Clin Proc. 2016;91(1):101\u201319.","journal-title":"Mayo Clin Proc"},{"issue":"8","key":"3715_CR4","doi-asserted-by":"crossref","first-page":"1589","DOI":"10.1182\/blood-2012-02-408922","volume":"120","author":"L Rosinol","year":"2012","unstructured":"Rosinol L, et al. Superiority of bortezomib, thalidomide, and dexamethasone (VTD) as induction pretransplantation therapy in multiple myeloma: a randomized phase 3 PETHEMA\/GEM study. Blood. 2012;120(8):1589\u201396.","journal-title":"Blood"},{"key":"3715_CR5","doi-asserted-by":"crossref","first-page":"10290","DOI":"10.1038\/ncomms10290","volume":"7","author":"DC Johnson","year":"2016","unstructured":"Johnson DC, et al. Genome-wide association study identifies variation at 6q25.1 associated with survival in multiple myeloma. Nat Commun. 2016;7:10290.","journal-title":"Nat Commun"},{"issue":"1","key":"3715_CR6","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1002\/ajh.24236","volume":"91","author":"SV Rajkumar","year":"2016","unstructured":"Rajkumar SV. Myeloma today: disease definitions and treatment advances. Am J Hematol. 2016;91(1):90\u2013100.","journal-title":"Am J Hematol"},{"issue":"9","key":"3715_CR7","doi-asserted-by":"crossref","first-page":"1269","DOI":"10.1016\/j.ejca.2008.03.005","volume":"44","author":"M Harland","year":"2008","unstructured":"Harland M, et al. A comparison of CDKN2A mutation detection within the melanoma genetics consortium (GenoMEL). Eur J Cancer. 2008;44(9):1269\u201374.","journal-title":"Eur J Cancer"},{"issue":"2","key":"3715_CR8","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1093\/hmg\/7.2.209","volume":"7","author":"N Soufir","year":"1998","unstructured":"Soufir N, et al. Prevalence of p16 and CDK4 germline mutations in 48 melanoma-prone families in France. The French familial melanoma study group. Hum Mol Genet. 1998;7(2):209\u201316.","journal-title":"Hum Mol Genet"},{"issue":"12","key":"3715_CR9","doi-asserted-by":"crossref","first-page":"894","DOI":"10.1093\/jnci\/94.12.894","volume":"94","author":"DT Bishop","year":"2002","unstructured":"Bishop DT, et al. Geographical variation in the penetrance of CDKN2A mutations for melanoma. J Natl Cancer Inst. 2002;94(12):894\u2013903.","journal-title":"J Natl Cancer Inst"},{"issue":"2","key":"3715_CR10","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1136\/jmg.2006.043802","volume":"44","author":"AM Goldstein","year":"2007","unstructured":"Goldstein AM, et al. Features associated with germline CDKN2A mutations: a GenoMEL study of melanoma-prone families from three continents. J Med Genet. 2007;44(2):99\u2013106.","journal-title":"J Med Genet"},{"issue":"7","key":"3715_CR11","doi-asserted-by":"crossref","first-page":"801","DOI":"10.1007\/s00405-007-0258-4","volume":"264","author":"M Fischer","year":"2007","unstructured":"Fischer M. Analysis of exon 2 of MTS1 in HPV-positive and HPV-negative tumors of the head and neck region. Eur Arch Otorhinolaryngol. 2007;264(7):801\u20137.","journal-title":"Eur Arch Otorhinolaryngol"},{"issue":"6","key":"3715_CR12","doi-asserted-by":"crossref","first-page":"692","DOI":"10.1002\/humu.21245","volume":"31","author":"HA McKenzie","year":"2010","unstructured":"McKenzie HA, et al. Predicting functional significance of cancer-associated p16(INK4a) mutations in CDKN2A. Hum Mutat. 2010;31(6):692\u2013701.","journal-title":"Hum Mutat"},{"issue":"5","key":"3715_CR13","doi-asserted-by":"crossref","first-page":"1869","DOI":"10.1182\/blood.V95.5.1869.005k09_1869_1871","volume":"95","author":"D Dilworth","year":"2000","unstructured":"Dilworth D, et al. Germline CDKN2A mutation implicated in predisposition to multiple myeloma. Blood. 2000;95(5):1869\u201371.","journal-title":"Blood"},{"issue":"12","key":"3715_CR14","doi-asserted-by":"crossref","first-page":"953","DOI":"10.1093\/jnci\/djs221","volume":"104","author":"B Mukherjee","year":"2012","unstructured":"Mukherjee B, et al. Risk of non-melanoma cancers in first-degree relatives of CDKN2A mutation carriers. J Natl Cancer Inst. 2012;104(12):953\u20136.","journal-title":"J Natl Cancer Inst"},{"key":"3715_CR15","doi-asserted-by":"crossref","first-page":"12050","DOI":"10.1038\/ncomms12050","volume":"7","author":"JS Mitchell","year":"2016","unstructured":"Mitchell JS, et al. Genome-wide association study identifies multiple susceptibility loci for multiple myeloma. Nat Commun. 2016;7:12050.","journal-title":"Nat Commun"},{"issue":"16","key":"3715_CR16","doi-asserted-by":"crossref","first-page":"1734","DOI":"10.1056\/NEJMc081677","volume":"359","author":"NJ Camp","year":"2008","unstructured":"Camp NJ, Werner TL, Cannon-Albright LA. Familial myeloma. N Engl J Med. 2008;359(16):1734\u20135. author reply 1735","journal-title":"N Engl J Med"},{"issue":"11","key":"3715_CR17","doi-asserted-by":"crossref","first-page":"1661","DOI":"10.1016\/j.ejca.2005.11.033","volume":"42","author":"A Altieri","year":"2006","unstructured":"Altieri A, et al. Familial risks and temporal incidence trends of multiple myeloma. Eur J Cancer. 2006;42(11):1661\u201370.","journal-title":"Eur J Cancer"},{"issue":"8","key":"3715_CR18","doi-asserted-by":"crossref","first-page":"1179","DOI":"10.3324\/haematol.2009.006346","volume":"94","author":"SY Kristinsson","year":"2009","unstructured":"Kristinsson SY, et al. Risk of solid tumors and myeloid hematological malignancies among first-degree relatives of patients with monoclonal gammopathy of undetermined significance. Haematologica. 2009;94(8):1179\u201381.","journal-title":"Haematologica"},{"issue":"19","key":"3715_CR19","doi-asserted-by":"crossref","first-page":"1479","DOI":"10.1093\/jnci\/93.19.1479","volume":"93","author":"HT Lynch","year":"2001","unstructured":"Lynch HT, et al. Familial multiple myeloma: a family study and review of the literature. J Natl Cancer Inst. 2001;93(19):1479\u201383.","journal-title":"J Natl Cancer Inst"},{"issue":"5","key":"3715_CR20","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1016\/S1097-2765(00)80351-2","volume":"3","author":"Y Zhang","year":"1999","unstructured":"Zhang Y, Xiong Y. Mutations in human ARF exon 2 disrupt its nucleolar localization and impair its ability to block nuclear export of MDM2 and p53. Mol Cell. 1999;3(5):579\u201391.","journal-title":"Mol Cell"},{"issue":"6","key":"3715_CR21","doi-asserted-by":"crossref","first-page":"725","DOI":"10.1016\/S0092-8674(00)81401-4","volume":"92","author":"Y Zhang","year":"1998","unstructured":"Zhang Y, Xiong Y, Yarbrough WG. ARF promotes MDM2 degradation and stabilizes p53: ARF-INK4a locus deletion impairs both the Rb and p53 tumor suppression pathways. Cell. 1998;92(6):725\u201334.","journal-title":"Cell"},{"issue":"49","key":"3715_CR22","doi-asserted-by":"crossref","first-page":"7017","DOI":"10.1038\/sj.onc.1210507","volume":"26","author":"YC Lin","year":"2007","unstructured":"Lin YC, et al. Human p16gamma, a novel transcriptional variant of p16(INK4A), coexpresses with p16(INK4A) in cancer cells and inhibits cell-cycle progression. Oncogene. 2007;26(49):7017\u201327.","journal-title":"Oncogene"},{"issue":"5","key":"3715_CR23","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1016\/S0092-8674(00)80452-3","volume":"91","author":"T Kamijo","year":"1997","unstructured":"Kamijo T, et al. Tumor suppression at the mouse INK4a locus mediated by the alternative reading frame product p19ARF. Cell. 1997;91(5):649\u201359.","journal-title":"Cell"},{"issue":"11","key":"3715_CR24","first-page":"2497","volume":"56","author":"A Borg","year":"1996","unstructured":"Borg A, et al. Novel germline p16 mutation in familial malignant melanoma in southern Sweden. Cancer Res. 1996;56(11):2497\u2013500.","journal-title":"Cancer Res"},{"issue":"11","key":"3715_CR25","doi-asserted-by":"crossref","first-page":"1273","DOI":"10.1093\/hmg\/11.11.1273","volume":"11","author":"C Hewitt","year":"2002","unstructured":"Hewitt C, et al. Germline mutation of ARF in a melanoma kindred. Hum Mol Genet. 2002;11(11):1273\u20139.","journal-title":"Hum Mol Genet"},{"issue":"1","key":"3715_CR26","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1038\/ng0994-27","volume":"8","author":"C Caldas","year":"1994","unstructured":"Caldas C, et al. Frequent somatic mutations and homozygous deletions of the p16 (MTS1) gene in pancreatic adenocarcinoma. Nat Genet. 1994;8(1):27\u201332.","journal-title":"Nat Genet"},{"issue":"3","key":"3715_CR27","first-page":"619","volume":"10","author":"Q Liu","year":"1995","unstructured":"Liu Q, et al. MTS-1 (CDKN2) tumor suppressor gene deletions are a frequent event in esophagus squamous cancer and pancreatic adenocarcinoma cell lines. Oncogene. 1995;10(3):619\u201322.","journal-title":"Oncogene"},{"issue":"33","key":"3715_CR28","doi-asserted-by":"crossref","first-page":"3911","DOI":"10.1200\/JCO.2014.59.1503","volume":"33","author":"BA Walker","year":"2015","unstructured":"Walker BA, et al. Mutational Spectrum, copy number changes, and outcome: results of a sequencing study of patients with newly diagnosed myeloma. J Clin Oncol. 2015;33(33):3911\u201320.","journal-title":"J Clin Oncol"},{"issue":"1","key":"3715_CR29","first-page":"127","volume":"16","author":"M Simon","year":"2006","unstructured":"Simon M, et al. Role of p16 and p14ARF in radio- and chemosensitivity of malignant gliomas. Oncol Rep. 2006;16(1):127\u201332.","journal-title":"Oncol Rep"},{"issue":"3","key":"3715_CR30","first-page":"501","volume":"17","author":"Y Iwadate","year":"2000","unstructured":"Iwadate Y, et al. Alteration of CDKN2\/p16 in human astrocytic tumors is related with increased susceptibility to antimetabolite anticancer agents. Int J Oncol. 2000;17(3):501\u20135.","journal-title":"Int J Oncol"},{"issue":"4","key":"3715_CR31","doi-asserted-by":"crossref","first-page":"868","DOI":"10.1158\/1078-0432.CCR-15-0481","volume":"22","author":"M Andreeff","year":"2016","unstructured":"Andreeff M, et al. Results of the phase I trial of RG7112, a small-molecule MDM2 antagonist in leukemia. Clin Cancer Res. 2016;22(4):868\u201376.","journal-title":"Clin Cancer Res"},{"issue":"9","key":"3715_CR32","volume":"9","author":"D Gu","year":"2014","unstructured":"Gu D, et al. Inhibition of the MDM2 E3 ligase induces apoptosis and autophagy in wild-type and mutant p53 models of multiple myeloma, and acts synergistically with ABT-737. PLoS One. 2014;9(9):e103015.","journal-title":"PLoS One"},{"issue":"5","key":"3715_CR33","doi-asserted-by":"crossref","first-page":"e185","DOI":"10.3324\/haematol.2015.139717","volume":"101","author":"B Reis","year":"2016","unstructured":"Reis B, et al. Acute myeloid leukemia patients' clinical response to idasanutlin (RG7388) is associated with pre-treatment MDM2 protein expression in leukemic blasts. Haematologica. 2016;101(5):e185\u20138.","journal-title":"Haematologica"},{"issue":"7","key":"3715_CR34","doi-asserted-by":"crossref","first-page":"743","DOI":"10.1038\/nm726","volume":"8","author":"B Linggi","year":"2002","unstructured":"Linggi B, et al. The t(8;21) fusion protein, AML1 ETO, specifically represses the transcription of the p14(ARF) tumor suppressor in acute myeloid leukemia. Nat Med. 2002;8(7):743\u201350.","journal-title":"Nat Med"}],"container-title":["BMC Cancer"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12885-017-3715-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,10,21]],"date-time":"2020-10-21T05:00:17Z","timestamp":1603256417000},"score":1,"resource":{"primary":{"URL":"http:\/\/bmccancer.biomedcentral.com\/articles\/10.1186\/s12885-017-3715-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,11,6]]},"references-count":34,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2017,12]]}},"alternative-id":["3715"],"URL":"https:\/\/doi.org\/10.1186\/s12885-017-3715-5","relation":{},"ISSN":["1471-2407"],"issn-type":[{"value":"1471-2407","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,11,6]]},"article-number":"718"}}